SIREN : 805239100
PHARPAMA is a French company founded 11 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in GEX (01170), this company of category PME shows in 2019 a revenue of 2.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-25
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | N/C | N/C | 2 585 550 € | 2 715 256 € | 2 590 931 € | 2 484 905 € |
| Net income | 145 908 € | 92 577 € | 176 804 € | 91 328 € | 97 073 € | 164 551 € | 151 346 € | 143 785 € | 198 752 € |
| EBITDA | N/C | N/C | N/C | N/C | N/C | 263 124 € | 242 822 € | 235 742 € | 336 221 € |
| Net margin | N/C | N/C | N/C | N/C | N/C | 6.4% | 5.6% | 5.5% | 8.0% |
In 2024, PHARPAMA generates positive net income of 146 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 199 k€ -> 146 k€.
145 908 €
The debt ratio (= Financial debt / Equity x 100) stands at 45%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 63%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
45.091%
63.065%
6.0%
In 2024, the debt ratio of PHARPAMA (45.09) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of PHARPAMA (63.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
The liquidity ratio (= Current assets / Current liabilities) stands at 192.24. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
192.244
In 2024, the liquidity ratio of PHARPAMA (192.24) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
0 €
0 j
0 j
0 j
Based on 225 transactions of similar company sales in 2024, the value of PHARPAMA is estimated at 2 036 983 € (range 1 418 523€ - 3 047 443€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARPAMA with other companies in the same sector:
The revenue of PHARPAMA in 2019 is 2.6 M€.
Yes, PHARPAMA generated a net profit of 146 k€ in 2024.
The headquarters of PHARPAMA is located in GEX (01170), in the department Ain.
The tax return of PHARPAMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARPAMA operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.